Parmax Pharma (BOM:540359) E10: ₹-2.98 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540359 Parmax Pharma Ltd BOM:540359
39 GF Score
Price ₹102.92
GF Value ₹25.56
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Parmax Pharma E10?

Parmax Pharma BOM:540359 +1.99% 39 E10 is ₹-2.98 as of Mar. 2026. GuruFocus rates BOM:540359 with a GF Score™ of 39/100 and a GF Value™ of ₹25.56 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Parmax Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹-1.560. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹-2.98 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-21), Parmax Pharma's current stock price is ₹102.92. Parmax Pharma's E10 for the quarter that ended in Mar. 2026 was ₹-2.98. Parmax Pharma's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Parmax Pharma was 175.00. The lowest was 59.00. And the median was 75.33.


Parmax Pharma  (BOM:540359) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Parmax Pharma was 175.00. The lowest was 59.00. And the median was 75.33.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Parmax Pharma E10 Related Terms


Parmax Pharma E10 Historical Data

* Premium members only.

The historical data trend for Parmax Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parmax Pharma E10 Chart

Parmax Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.50 -1.04 -1.77 -2.98

Parmax Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.77 -2.00 -2.58 -2.79 -2.98

BOM:540359 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Parmax Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parmax Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parmax Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Parmax Pharma's Shiller PE Ratio falls into.


BOM:540359
39GF Score
Parmax Pharma Ltd BOM:540359
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parmax Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Parmax Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-1.56/164.2724*164.2724
=-1.560

Current CPI (Mar. 2026) = 164.2724.

Parmax Pharma Quarterly Data

per share eps CPI Adj_EPS
201606 0.011 105.961 0.017
201609 0.002 105.961 0.003
201612 -0.010 105.196 -0.016
201703 0.020 105.196 0.031
201706 -0.590 107.109 -0.905
201709 -0.290 109.021 -0.437
201712 0.100 109.404 0.150
201803 1.520 109.786 2.274
201806 0.160 111.317 0.236
201809 -1.480 115.142 -2.112
201812 -0.780 115.142 -1.113
201903 2.307 118.202 3.206
201906 -0.760 120.880 -1.033
201909 1.550 123.175 2.067
201912 2.720 126.235 3.540
202003 -2.362 124.705 -3.111
202006 -2.660 127.000 -3.441
202009 1.380 130.118 1.742
202012 4.110 130.889 5.158
202103 -0.830 131.771 -1.035
202106 -1.160 134.084 -1.421
202109 3.050 135.847 3.688
202112 -1.380 138.161 -1.641
202203 -0.123 138.822 -0.146
202206 -3.520 142.347 -4.062
202209 -1.880 144.661 -2.135
202212 4.660 145.763 5.252
202303 0.460 146.865 0.515
202306 -3.150 150.280 -3.443
202309 -3.660 151.492 -3.969
202312 -4.680 152.924 -5.027
202403 -3.877 153.035 -4.162
202406 0.030 155.789 0.032
202409 -1.880 157.882 -1.956
202412 -1.050 158.323 -1.089
202503 -4.000 157.552 -4.171
202506 -2.040 159.755 -2.098
202509 -5.560 162.289 -5.628
202512 -1.960 163.281 -1.972
202603 -1.560 164.272 -1.560

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹-2.98 mean?
Parmax Pharma (BOM:540359) has a E10 of ₹-2.98 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Parmax Pharma and its competitors.
Is Parmax Pharma's E10 too high?
Parmax Pharma's current E10 is ₹-2.98. Overall, Parmax Pharma has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Parmax Pharma's E10 compare to ZTS and UTHR?
Parmax Pharma's E10 of ₹-2.98 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Parmax Pharma and its competitors. Parmax Pharma's current E10 is ₹-2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parmax Pharma stock overvalued right now?
Based on GuruFocus' analysis, Parmax Pharma (BOM:540359) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹25.56, compared to a current price of ₹102.92 — trading 302.7% above its estimated fair value. The current E10 is ₹-2.98. Parmax Pharma's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Parmax Pharma (BOM:540359), the current E10 is ₹-2.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Parmax Pharma (BOM:540359) Overvalued in 2026?

Based on GuruFocus' analysis, Parmax Pharma stock appears to be overvalued. The current stock price of ₹102.92 is trading 302.7% above its estimated GF Value™ of ₹25.56. GuruFocus considers Parmax Pharma to be Significantly Overvalued.

Key valuation signals for BOM:540359:

  • E10: ₹-2.98
  • GF Value™: ₹25.56 vs. price of ₹102.92 (302.7% above fair value)
  • GF Score™: 39/100 with 8 warning signs

No single metric tells the full story. See the BOM:540359 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Parmax Pharma Business Description

Address Rajkot-Gondal National Highway No. 27, Plot No. 20, Survey No. 52, Taluka Kotda Sangani, Hadamtala, Rajkot, GJ, IND, 360 311
Parmax Pharma Ltd is a pharmaceutical company. The company manufactures and sells Tablets, Capsules, Ointments, and injectables. Its Core Segments: Anti-infectives, Analgesics & anti-inflammatory, Cardiovascular APIs, General oral formulations (tablets, capsules) Its products include Aripiprazole, Lamotrigine I.P., Nebivolol Hydrochloride, Indapamine USP, Voglibos, Paliperidone, Lacosamide, 2-Acetyl Benzo(B) Thiophene, Camphor Sulfonyl Chloride, 3-Methoxy Thiophene, Silodosin API, and others.
39GF Score

Get the complete analysis for BOM:540359

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹102.92
Price
₹25.56
GF Value